Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in ratsARTICLE

European Journal of Clinical Investigation

Volumn 40, Issue 4, 2010, Pages 301-309

  Ke, Chun Yen ^a   Lee, Chia Chi ^b   Lee, Chung Jen ^b   Subeq, Yi Maun ^a   Lee, Ru Ping ^a   Hsu, Bang Gee ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Aliskiren; Chlorhexidine digluconate; Peritoneal fibrosis

Indexed keywords

ALISKIREN; ALPHA SMOOTH MUSCLE ACTIN; CHLORHEXIDINE GLUCONATE; COLLAGEN; DIANEAL; FIBRONECTIN; GLUCOSE; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1; UREA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETER; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIALYSATE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LIVER; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MICROSCOPY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT DURATION; UREA BLOOD LEVEL;

AMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; CHLORHEXIDINE; FUMARATES; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; RENIN; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 77949713481     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02264.x     Document Type: Article

References (31)

1. Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol 2008 23 : 19 25.
2. Goffin E. Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial 2008 21 : 258 265.
3. Summers AM, Hoff CM, Topley N. How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis? Perit Dial Int 2008 5 : S16 20.
4. Schmidt DW, Flessner MF. Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research. Perit Dial Int 2008 28 (Suppl. 5 S10 5.
5. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009 111 : c149 54.
6. Park SH, Kim YL, Lindholm B. Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 2008 28 (Suppl. 5 S21 8.
7. Witowski J, Jörres A. Preventing peritoneal fibrosis - an ace up our sleeve? Perit Dial Int 2005 25 : 25 9.
8. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005 25 : 38 47.
9. Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol 1999 31 : 395 403.
10. Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int 2007 27 (Suppl. 2 S82 6.
11. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006 1 : 221 228.
12. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008 7 : 399 410.
13. Chen TM, Subeq YM, Lee RP, Chiou TW, Hsu BG. Single dose intravenous thioacetamide administration as a model of acute liver damage in rats. Int J Exp Pathol 2008 89 : 223 231.
14. Lee CC, Lee RP, Subeq YM, Lee CJ, Chen TM, Hsu BG. Fluvastatin attenuates severe hemorrhagic shock-induced organ damage in rats. Resuscitation 2009 80 : 372 378.
15. Subeq YM, Wu WT, Lee CJ, Lee RP, Yang FL, Hsu BG. Pentobarbital reduces rhabdomyolysis induced acute renal failure in conscious rats. J Trauma 2009 67 : 132 138.
16. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005 23 : 417 426.
17. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007 22 : 2838 2848.
18. Komatsu H, Uchiyama K, Tsuchida M, Isoyama N, Matsumura M, Hara T et al. Development of a peritoneal sclerosis rat model using a continuous-infusion pump. Perit Dial Int 2008 28 : 641 647.
19. Saito H, Kitamoto M, Kato K, Liu N, Kitamura H, Uemura K et al. Tissue factor and factor v involvement in rat peritoneal fibrosis. Perit Dial Int 2009 29 : 340 351.
20. Di Paolo N, Nicolai GA, Garosi G. The peritoneum: from histological studies to mesothelial transplant through animal experimentation. Perit Dial Int 2008 28 (Suppl. 5 S5 9.
21. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995 47 : 287 291.
22. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003 64 : 887 896.
23. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004 65 : 1927 1936.
24. Faull RJ. Bad and good growth factors in the peritoneal cavity. Nephrology 2005 10 : 234 239.
25. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001 12 : 2029 2039.
26. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008 52 : 130 136.
27. Bozkurt D, Cetin P, Sipahi S, Hur E, Nar H, Ertilav M et al. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit Dial Int 2008 28 (Suppl. 5 S38 42.
28. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 308 : 698 705.
29. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005 25 : 483 491.
30. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007 13 (8 Suppl. B 9 20.
31. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009 10 : 1 8.